Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
17/08/2026 12:31
BRIEF-Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer Aug 17 (Reuters) - Faeth Therapeutics, Inc FTH.O:
FAETH THERAPEUTICS ANNOUNCES FDA GRANT OF FAST TRACK DESIGNATION FOR PIKTOR PLUS PACLITAXEL IN BIOMARKER-SELECTED ADVANCED ENDOMETRIAL CANCER
FAETH THERAPEUTICS - TOPLINE DATA FROM PHASE 2 TRIAL IN ADVANCED ENDOMETRIAL CANCER EXPECTED BY YEAR-END 2026
FAETH THERAPEUTICS - INTERIM DATA FROM PHASE 1B/2 TRIAL IN ADVANCED BREAST CANCER EXPECTED IN 2027
Source text: ID:nBw8JcGzra
Further company coverage: FTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments